Sugi Predict

Sugi Predict / Targets / MYO3A

MYO3A

Myosin-IIIa · Q8NEV4 · MYO3A on Sugi Atlas →

0 patent compounds predicted against MYO3A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MYO3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection PHASE1UNKNOWN
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill nanUNKNOWN
Molecular and Genetic Studies of Congenital Myopathies nanRECRUITING
Precision Medicine for Nociception, Sngception and Proprioception. nanRECRUITING
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Genetic Testing in Primary Congenital Glaucoma Patients nanUNKNOWN
Characteristics of Nondystrophic Myotonias nanCOMPLETED
Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies nanRECRUITING
Natural History Study for Patients With Nemaline Myopathy in Belgium nanNOT_YET_RECRUITING
Chronic Muscle Disuse in the Elderly nanCOMPLETED
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium nanCOMPLETED
Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia nanCOMPLETED
Congenital Muscle Disease Study of Patient and Family Reported Medical Information nanRECRUITING
Myotubular and Centronuclear Myopathy Patient Registry nanRECRUITING
3D-Microscopic Muscle Architecture in Cerebral Palsy nanRECRUITING
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment nanCOMPLETED
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
Registry of Unexplained Cardiac Arrest nanCOMPLETED
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
Role of Ultrasound in Diagnosis of Muscle Diseases nanCOMPLETED
LGMD R1 Natural History Study nanACTIVE_NOT_RECRUITING
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD nanENROLLING_BY_INVITATION
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING
Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies nanRECRUITING
The Muscle in Cerebral Palsy; Sarcomere Length in Vivo and Microscopic Characterization of Biopsies. nanRECRUITING
Inspiratory Muscle Training in Nemaline Myopathy nanCOMPLETED
Contractile Cross Sectional Areas and Muscle Strength in Patients With Congenital Myopathies nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MYO3A binder may also engage these)

ProteinNameSimilarity
Q8K3H5 — 1.000 Q8K3H5 →
MYO3B Myosin-IIIb 1.000 landscape →
Q9V3Z6 — 0.996 Q9V3Z6 →
A5PF48 — 0.995 A5PF48 →
Q6GPA1 — 0.995 Q6GPA1 →
Q622K8 — 0.994 Q622K8 →
Q01989 — 0.994 Q01989 →
Q8N1T3 — 0.993 Q8N1T3 →
P91443 — 0.992 P91443 →
Q99MZ6 — 0.991 Q99MZ6 →
Q29P71 — 0.991 Q29P71 →
F8VQB6 — 0.991 F8VQB6 →
P97479 — 0.990 P97479 →
Q1EG27 — 0.989 Q1EG27 →
O94832 — 0.989 O94832 →
Q9Y2K3 — 0.989 Q9Y2K3 →
P22467 — 0.988 P22467 →
Q6PIF6 — 0.988 Q6PIF6 →
Q13402 — 0.988 Q13402 →
Q63357 — 0.988 Q63357 →
Q9HD67 — 0.987 Q9HD67 →
D3ZJP6 — 0.987 D3ZJP6 →
O74805 — 0.987 O74805 →
A7E2Y1 — 0.986 A7E2Y1 →
O14157 — 0.986 O14157 →
Q5SYD0 — 0.986 Q5SYD0 →
P24733 — 0.986 P24733 →
F1PRN2 — 0.985 F1PRN2 →
Q17R14 — 0.985 Q17R14 →
Q9USI6 — 0.985 Q9USI6 →